• Publications
  • Influence
Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
TLDR
It is demonstrated that the fixed combination of travoprost/timolol produces significant and clinically relevant reductions of IOP in a once-daily dosing regimen, and reductions that were similar to concomitant traVoprost + timolol. Expand
Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
TLDR
Travoprost 0.004% was more effective than latanoprost and timolol in reducing intraocular pressure in black patients by up to 2.5% in patients with open-angle glaucoma or ocular hypertension and is safe and generally well tolerated in the studied patient population. Expand
Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.
TLDR
Anecortave acetate (15 mg) is safe and clinically efficacious at 1 year for maintaining vision, preventing severe vision loss, and inhibiting subfoveal CNV lesion growth. Expand
Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension
TLDR
The significantly larger IOP reduction with travoprost compared with timolol in both racial groups was more pronounced in blacks, and Travoprost was superior to latanoprost in blacks. Expand
A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues.
TLDR
A novel method to predict the human ocular penetration and distribution of topical antibiotics by using a controlled rabbit model that mimics the human eye with manual blinking and tear flow is established and moxifloxacin achieved the highest levels of antibiotic in ocular tissues. Expand
Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
TLDR
The safety and efficacy outcomes in this study demonstrate that the benefits of anecortave acetate for the treatment of choroidal neovascularization outweigh the risks associated with either the drug or the PJD administration procedure. Expand
Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.
TLDR
Clinical studies show that travoprost 0.004% (isopropyl ester) provided intraocular pressure control superior to timolol 0.5% when used as monotherapy in patients with open-angle glaucoma or ocular hypertension, and AL-6598 0.01% provided a sustained intraocular Pressure reduction with q.i.d. application. Expand
Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked
TLDR
In the patients studied, olopatadine 0.2% appeared to be effective and well tolerated when administered once daily for the treatment of the ocular signs and symptoms of allergic conjunctivitis or rhinoconjunctivoitis. Expand
Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis*
TLDR
For the subjects enrolled in these studies, olopatadine 0.2% appeared to be safe, well-tolerated, and effective in significantly reducing the frequency and/or severity of some effects of pollen on nasal symptoms. Expand
Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
TLDR
Once-daily dosing with olopatadine 0.2% reduced the signs and symptoms of allergic conjunctivitis with a rapid and prolonged duration of action. Expand
...
1
2
3
4
5
...